Hepatic encephalopathy (HE) is a disabling consequence (BZR) appears to play an important role in hepatic encepha-of advanced liver disease, but the pathophysiology of HE lopathy (HE). However, there is controversy regarding remains unclear. Several lines of evidence support a role whether the density or affinity of BZRs is altered. A previous for increased activity of the central benzodiazepine receptor positron emission tomography (PET) study using the BZR (BZR) in HE. The BZR is a component of the g-aminobutyric antagonist [ 11 C]flumazenil (FMZ) found two-to threefold acid (GABA A ) chloride channel. Activation of the BZR results greater cerebral cortical tracer uptake in recurrent HE, but in an increased sensitivity of the GABA A receptor to agonists did not account for impaired FMZ metabolism due to liver and increased activity of the GABA A chloride channel.
for withdrawal of timed blood samples. A dynamic series of PET tion would then result in overestimation of BZR density. We images was obtained over 60 minutes together with arterial blood considered that this was probably the reason for the increase samples after the bolus injection of approximately 20-50 mCi of in brain FMZ activity reported previously. In the present tions with the application of a quantitative tracer kinetic labeled, polar metabolites were determined chromatographically as method for estimation of FMZ binding to GABA A receptors described previously. 21 that accounts for effects on peripheral radiotracer metabolism
The blood and PET data were analyzed according to a two-comby direct measurement and chromatography of arterial partment, two-parameter tracer kinetic model, resulting in pixelplasma. [21] [22] [23] by-pixel parametric images of tracer transport (K 1 ) and binding (represented by the total tracer tissue distribution volume [DV]).
PATIENTS AND METHODS
Prior studies have identified the physiological sensitivity and specificity of these parameters and indicate a lack of confounding effects Subjects. Nine patients with recurrent HE and 13 age-comparable of cerebral blood flow on estimates. 22, 23, 26 controls were studied. The patients were all undergoing evaluation After calculation of the K 1 and DV images, we spatially deformed for liver transplantation and took lactulose daily for control of sympindividual brains to a common reference anatomic format. The detoms of chronic HE. Clinical details of these 9 patients are presented formation procedure makes use of the K 1 image for anatomic feature in Table 1 . The severity of liver disease was estimated using the definition and adjusts both the scale and the shape of each brain Child-Pugh score. 24 Three patients had liver disease from ethanol, with sequential application of linear and nonlinear thin-plate spline two had cryptogenic cirrhosis, and one each had autoimmune hepadeformations as described previously. 27 Average images of K 1 and titis, hepatitis C, primary sclerosing cholangitis, and type III glycoof DV were then constructed for the HE and control groups. These gen-storage disease. Cirrhosis is an unusual sequela of type III glycowere sampled according to prospectively designated regions of ingen-storage disease, and the clinical details of this patient have been terest (ROIs), and were additionally explored on a voxel-by-voxel reported previously. 25 Five patients had transjugular intrahepatic basis for unanticipated focal differences. 28 portosystemic shunts (TIPS), and one had a distal splenorenal shunt Statistics. Blood FMZ and metabolism indices and brain ROI data for control of variceal hemorrhaging. Patency of the TIPS was conwere assessed with pairwise Student's t tests. Exploratory pixel-byfirmed by Doppler ultrasonography within 2 weeks of the study.
pixel analyses employed correction for multiple parallel compariNo patient had received sedatives for at least 5 weeks before the sons, assuming 9-mm 3 resolution in the reoriented images, correstudy. All 9 had had recurrent episodes of acute or chronic HE, sponding to approximately 980 independent gray-matter resolution although none had greater than grade I HE on the day of the study. elements in the PET images. 28 A statistical threshold of P õ .05 There were 7 men and 6 women in the control group, all of was used to identify significant group differences in all analyses. whom were free of significant general medical, neurological, and psychiatric illness and had no history of first-degree relatives with RESULTS familial neurological or psychiatric disease. The median age was 59 years (mean SD, 57 { 7 years; range, 45-65 years) and was not
The integrated arterial 11 C activity from unmetabolized, significantly different from that in the patient group.
intact [ 11 C]FMZ was similar for the two groups over the hour All subjects were screened to exclude history of head trauma with of the PET imaging study (Table 2) . However, the arterial loss of consciousness, recent drug or alcohol abuse or dependence, smoking, excessive consumption of caffeine, and, in the case of 11 C activity due to polar, radiolabeled, FMZ metabolites was control subjects, use of centrally acting medications within 12 significantly greater in the control group. When arterial months of participation. The studies were approved by the Univer-tracer time courses were examined in detail, substantial elesity of Michigan Institutional Review Boards governing studies in-vations of the terminal FMZ concentrations were observed volving human subjects and the use of radioactivity in humans. in HE, despite similar total arterial radioactivity levels in Written informed consent was obtained for all studies.
the two groups ( Fig. 1) . At 60 minutes postinjection, the PET Imaging. The blood-brain transport and binding of FMZ to percentage of arterial 11 C activity due to authentic FMZ was the central BZR on the GABA A -chloride ionophore complex were almost 70% higher in the patients than in the control group.
determined as previously described. 21 In brief, subjects were posiInspection of cerebral tracer time activity curves revealed tioned supine in the gantry of a Siemens/CTI 931/08-12 tomograph characteristic shape differences between HE and control sub- substantial overestimation of FMZ binding, emphasizing the need to chromatographically determine arterial ligand concentrations in future PET studies of HE. protracted retention in HE (Fig. 1C) , similar to those preWe found a trend toward increased global (whole brain) viously reported. 16 However, after compartmental physiological model applications to the activity curves, there were no significant differences either in whole brain or in regional FMZ K 1 in HE versus the normal control groups (Table 3) . There was a trend toward increased whole brain average [
11 C]FMZ DV in patients with recurrent HE that was not statistically significant (P Å .065; Table 3 , Fig. 2 ). Additionally, there was no correlation between the severity of liver disease (Fig. 3) or the presence of a portosystemic shunt and whole brain [
11 C]FMZ DV. When specific ROIs were examined, patients with HE showed modest (13%-23%) but statistically significant increases in [
11 C]FMZ DV in the thalamus, cerebellum, and pons (Fig. 4, Table 3 ). Although there were trends toward increased FMZ DV (10%-12%) in the putamen and cerebral cortex of the patient group, these were not statistically significant. The changes in the putamen were representative of those occurring elsewhere in the basal ganglia. The voxel-by-voxel analysis of FMZ DV confirmed that the largest between-group differences were in the thalamic and cerebellar regions but did not suggest additional areas of change that had been overlooked in the a priori ROI analyses. ity. 16 Our data reproduce the prior observation of comparable ses reveal FMZ DV of 5.62 and 6.79 in the temporal cortices of the control total blood activity levels and distinctly different cerebral and HE subjects, respectively, rather than the threefold binding difference suggested by the cerebral tracer levels at 60 minutes, evident in C. 21 were sampled from stereotacticallyplaced ROI as described previously. 28 Values represent means and SD for K 1 (mL plasma/mL brain/min) or DV (mL plasma/mL brain). Volume-weighted average of cerebral cortical activity in the scanned field-of-view.
DISCUSSION
* Volume-weighted average of cerebral gray matter in the scanned field-of-view as determined on the basis of K 1 values. 28 † P õ 0.05, ‡P õ 0.01, #P Å 0.065 vs. control.
FMZ binding in HE that was not statistically significant and studies have also failed to detect a significant increase in the density of BZRs or GABA A receptors in HE. 3, 29, 30 was not correlated with the severity of liver disease in individual patients as gauged by their Child-Pugh scores. 24 It In contrast to cortical and basal ganglia BZR binding, we detected statistically significant increases in [
11 C]FMZ bindshould be noted, however, that 6 of the 9 patients had portosytemic shunts, and the lack of correlation may be due to ing in the thalamus, pons, and cerebellum. These localized increases in [ 11 C]FMZ binding could be due to a variety of confounding favorable effects of the shunts on ascites and hepatic biochemical function. Additionally, the multifactorial factors. Only unbound (free) plasma FMZ is available to cross the blood-brain barrier. From this pool, only unmetabnature of exacerbations of chronic HE is well recognized, and alterations in central BZR density or affinity might reflect olized FMZ has been shown to cross the intact blood-brain barrier. 20 FMZ has a relatively low binding of plasma protein recent biochemical fluctuations to a greater extent than the long-term effects of hepatic insufficiency. Nevertheless, our binding; approximately 40% is plasma protein bound in normal volunteers. 31 Although patients with advanced liver disdata do not support a major role of elevated whole brain BZR density in the clinical phenomenology of HE responsiveness ease have been shown to have reduced plasma protein binding of [ 11 C]FMZ, 18 we believe that the potential increase of to BZR antagonists. We found insignificant, minor trends toward increased FMZ binding in the cerebral cortex and free plasma [
11 C]FMZ in the patient group has not had a major impact on our data. If increased free FMZ were imbasal ganglia of patients with HE. Our binding data are thus in general agreement with the findings of the autopsy study portant in distinguishing our groups, we would expect global rather than regional effects on DV. Furthermore, effects on of Butterworth et al., 17 which reported a lack of change in either the density or the affinity of BZRs in the cerebral both blood-brain transport (K 1 ) as well as FMZ binding (DV) should be observed in this instance. Our data indicate subcortex or caudate nucleus of patients who died of HE. Animal stantial regional variations in DV increases, from only 10% in the cerebral cortex to more than 20% in the pons and cerebellum and reveal only minor effects on K 1 (2%-14%) that appear maximal in the basal ganglia and thalamus, and least in the cerebellum where DV is most significantly increased. This means that significant permeability changes in the blood-brain barrier are unlikely. The major pathway for metabolism of FMZ in normal hu-density. Previous PET measures of cerebral blood flow and glucose metabolism in HE have suggested subcortical inman subjects is via ester hydrolysis, resulting in a carboxylic acid metabolite designated Ro 15-3890.
32,33 Ro 15-3890 is creases, particularly in the cerebellum, thalamus, and caudate. 34 Although we find no evidence of significant FMZ DV more polar than FMZ and is therefore unable to cross the blood-brain barrier. Persson et al. 20 directly verified this pre-change in the caudate nucleus, the overlap of our binding data with the metabolic changes in these regions suggests diction in studies of the cerebral uptake of [ 11 C]Ro 15-3890 in healthy volunteers, demonstrating no detectable entry into that they may be preferentially involved in the cerebral response to hepatic failure. the brain after its systemic administration. Furthermore, we have confirmed directly in rats that the major radioactive
In conclusion, we have shown that there is no significant increase in whole brain or in cerebral cortical [ 11 C]FMZ bindmetabolites of [ 11 C]FMZ do not enter the brain. 21 Formation of a hydroxyl ester at the same position, or N-demethylation ing in patients with recurrent HE, although there are regional increases in the thalamus and cerebellar cortex. These re-(potentially resulting in 11 CO 2 ), are both theoretical metabolic pathways for FMZ, but evidence of either of these prod-gional changes are most likely a result of increases in BZR density, but parallel or independent increases in BZR affinity ucts has not been found in baboon or human [ 11 C]FMZ PET studies. 32, 33 Increased permeability of the blood-brain barrier cannot be entirely excluded. Further study is now indicated to determine the cellular localization and neurochemical to polar [ 11 C]FMZ metabolites or the production of abnormal, less polar labeled metabolites could lead to increased mechanisms responsible for the regional increases in central BZR binding in recurrent HE. brain activity, mimicking increased BZR binding in HE. However, this effect, as with altered plasma protein binding, is REFERENCES predicted to result in global changes rather than the regional density (Bmax) to affinity (Kd). 21, 23 Thus, our findings could 
